TFO
RCUS icon

Tarbox Family Office’s Arcus Biosciences RCUS Stock Holding History

Tarbox Family Office’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,000
Closed -$35K – 1175
2021
Q3 		$35K Hold
1,000
– – 0.01% 287
2021
Q2 		$27K Buy
+1,000
New +$28.6K ﹤0.01% 332

Other funds holding RCUS

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Tarbox Family Office's RCUS Position: Q4 2021 in Review

Tarbox Family Office sold out of Arcus Biosciences (RCUS) in Q4 2021, closing a stake of 1,000 shares — an estimated $35K sold.

Tarbox Family Office first reported a position in RCUS in Q2 2021 and held it in 2 quarters. The position peaked at $35K in Q3 2021. 142 funds tracked by Wall St. Rank hold RCUS as of Q4 2021.

  • Tarbox Family Office reported no remaining Arcus Biosciences position as of Q4 2021 after selling out during the quarter.
  • Tarbox Family Office sold 1,000 Arcus Biosciences shares in Q4 2021, an estimated $35K.
  • Tarbox Family Office first reported a position in Arcus Biosciences in Q2 2021 and held it in 2 quarters.
  • Tarbox Family Office's Arcus Biosciences position peaked at $35K in Q3 2021.
  • 142 funds tracked by Wall St. Rank held Arcus Biosciences as of Q4 2021.

Based on Tarbox Family Office's 13F filing for Q4 2021, filed 6 Jan 2022.